1 / 16

Farmers’ Perceptions of Biopharming: Insights from a Tobacco Biopharming Survey

Farmers’ Perceptions of Biopharming: Insights from a Tobacco Biopharming Survey . Genti Kostandini Michelle Hayes. Biopharming. Third generation of GM crops Biopharming is the cultivation of crops for pharmaceutical purposes

nailah
Download Presentation

Farmers’ Perceptions of Biopharming: Insights from a Tobacco Biopharming Survey

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Farmers’ Perceptions of Biopharming: Insights from a Tobacco Biopharming Survey GentiKostandini Michelle Hayes

  2. Biopharming • Third generation of GM crops • Biopharming is the cultivation of crops for pharmaceutical purposes • Plants can “manufacture” therapeutic proteins, monoclonal antibodies, and vaccines (therapeutics) • Some therapeutics include: cancer, HIV, diabetes, Alzheimer's, hepatitis B, malaria, cystic fibrosis, and cholera

  3. Importance • Significantly cheaper than current production of abiotic fermentation (E. Coli or yeast) or mammalian cell cultures (Chinese hamster ovary cells) • More stable supply and increase consumer access • Reduces the chance of contamination from human or animal viruses • Possibility to develop new therapeutics

  4. Concerns • Can biopharmed crops be fully segregated? • Are there long term health effects? • How toxic are biopharmed crops to wildlife? • How long do compounds stay in the soil?

  5. Background • Dow AgroSciences- poultry vaccine from tobacco cells (U.S., 2006) • Planet Biotechnology- CaroRx , dental cavity treatment, from tobacco (E.U., 2006) • Hepatitis B antibody (Cuba, 2006) • Protalix/ Pfzier- Eleyso, Gauncher’s disease treatment, from carrot cells (U.S. & Israel, 2012)

  6. Study • Provide insights on producers knowledge of biopharming • Find out who is willing to participate and under what conditions • July 2012- telephone survey of 1,129 tobacco producers with a 14% response rate • 145 participants from Georgia, Kentucky, North Carolina, Tennessee, and Virginia

  7. Data • Primary data • Concerns about biopharming • Willingness to grow pharmaceutical tobacco under certain conditions regarding production methods and net return per acre • Knowledge of biopharming prior to the survey • Characteristics such as gender, age and income

  8. Data cont.

  9. Data cont.

  10. Willingness to GrowProduction • (a) Would you be willing to grow tobacco using current equipment and production methods for a pharmaceutical company if your net return per acre was [5%, 10%, 25%, 40%, 50% or more] more than growing conventional tobacco? • (b) If required to change current production methods would you be willing to grow transgenic tobacco for a pharmaceutical company if your net return per acre was [5%, 10%, 25%, 40%, 50% or more] more than growing conventional tobacco? • (c) If required to purchase additional equipment and change production methods would you be willing to grow transgenic tobacco for a pharmaceutical company if your net return per acre was [5%, 10%, 25%, 40%, 50% or more] more than growing conventional tobacco?

  11. Results

  12. Table 5. Willingness to grow under different production scenarios

  13. Willingness to growRegulations • 1320 ft. fallow zone from other fields • 1 year restriction to grow non-pharmaceutical crops after they have planted biopharming crops • Several annual inspections from regulatory agencies

  14. Table 6. Regulations and adoption

  15. Conclusions • Tobacco producers are willing to participate when economic incentives exist • Not much concern despite unfamiliarity with biopharming • Low awareness implies more information needs to be provided for producers • Producers’ opinions may help shape regulations

  16. Thank YOU

More Related